iLncDA-PT

Introduction


Exploring disease mechanism at the molecular level provides valuable guidance for disease prognosis and therapy, and most researches mainly focused on the genetic or protein levels. However, the emergence and progression of complex diseases are intricately linked to lncRNAs, and comprehensive analysis of complex diseases from the lncRNA perspective has been rarely explored. In this end, A systemic pipeline is proposed, which aims to identify disease-associated lncRNAs to prognosis and treatment of HCC. More specifically, due to the importance of identifying disease-associated lncRNA and the weak interpretability of existing computational identification methods, we propose a novel approach named iLncDA-PT to identify disease-associated lncRNAs considering the interactions between various bio-entities, and then we conduct a systematically molecular pathogenesis analysis on prognosis and therapy for specific disease, hepatocellular carcinoma (HCC), as an example. Finally, we reveal a significant association between immune checkpoint expression, tumor microenvironment, and drug treatment.

Figure.1 Framework of iLncDA-PT.

References

Upon the usage the users are requested to use the following citation:

·Wenxiang Zhang, Hang Wei, Wenjing Zhang, Bin Liu.
A systemic pipeline of identifying lncRNA-disease associations to the prognosis and treatment of hepatocellular carcinoma. IEEE Transactions on Big Data, 2024. DOI: 10.1109/TBDATA.2024.3433380.




Introduction

In this work, we introduce iLncDA-PT method, from lncRNA-disease association identification, further to the application of identified lncRNAs on disease prognosis and treatment. iLncDA-PT can serve as a useful tool for identifying disease-associated lncRNAs and personalized drug treatment.

NOTE

If you are interested in this research area or have any questions, please do not hesitate to contact us and we will do our best to answer them in order to facilitate mutual learning and progress. If you use our research results, please cite this article.

Copyright © bliu@bliulab rights reserved.

Back to home